Please use this identifier to cite or link to this item:
http://hdl.handle.net/11189/4737| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Báthori, Nikoletta B | - |
| dc.contributor.author | Lemmerer, Andreas | - |
| dc.contributor.author | Gerhard A, Venter | - |
| dc.contributor.author | Susan A, Bourne | - |
| dc.contributor.author | Mino R, Caira | - |
| dc.date.accessioned | 2016-07-26T10:29:21Z | - |
| dc.date.available | 2016-07-26T10:29:21Z | - |
| dc.date.issued | 2011 | - |
| dc.identifier.uri | http://dx.doi.org/10.1021/cg100670k | - |
| dc.identifier.uri | http://hdl.handle.net/11189/4737 | - |
| dc.description.abstract | The co-crystals of three industrially important pharmaceutical molecules, the Vitamin B group member nicotinamide (1), the antihyperlipidemic drug clofibric acid (2), and the nonsteroidal anti-inflammatory drug diclofenac (3), are synthesized with the co-crystal former isonicotinamide and characterized by thermal analysis and single crystal X-ray diffraction. Two dimorphic hydrates of isonicotinamide were obtained during the course of these experiments: hydrate 4 (form I) has been reported recently, and hydrate 5 (form II) is new. Both are monohydrates but differ in the number of independent molecules in the asymmetric unit, Z0 =2 and 8, respectively. Form II is metastable compared to I and converts to form I in the solid state. In all three pharmaceutical co-crystals, it is the pyridine N atom of either the nicotinamide molecule in 1 or the N atom of the isonicotinamide molecule in 2 and 3 that is used in connecting the different molecules together, as a hydrogen bond acceptor from the amine of the isonicotinamide in 1 and the carboxylic acid protons in 2 and 3. The carboxylic acid333 pyridine hydrogen bond is an often used supramolecular synthon. A survey of relevant structures in the Cambridge Structural Database of isonicotinamide and nicotinamide co-crystals is given for completeness, and the co-crystal former ability of isonicotinamide and nicotinamide was investigated by performing density functional theory calculations. | en_US |
| dc.description.sponsorship | Financial support was received from the South African National Research Foundation (NRF) (Grant FA2006030100003). A.L. thanks the NRF for a postdoctoral scholarship (SFP2006061500015). | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Crystal Growth and Design | en_US |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/3.0/za/ | en |
| dc.subject | Pharmaceutical Co-crystals | en_US |
| dc.subject | Isonicotinamide-Vitamin B3 | en_US |
| dc.subject | Clofibric Acid | en_US |
| dc.subject | Diclofenac | en_US |
| dc.title | Pharmaceutical co-crystals with isonicotinamide – vitamin B3, clofibric acid, and diclofenac – and two isonicotinamide hydrates | en_US |
| dc.type.patent | Article | en_US |
| Appears in Collections: | Appsc - Journal Articles (DHET subsidised) | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Báthori_Nikoletta_B_Lemmerer_Andreas_Gerhard_A_Venter_Susan_A_Bourne_Mino_R_Caira_AppSci_2011.pdf | Main Article | 1.47 MB | Adobe PDF | View/Open |
Page view(s)
67
Last Week
0
0
Last month
0
0
checked on Sep 2, 2026
Download(s)
29
checked on Sep 2, 2026
Google ScholarTM
Check
This item is licensed under a Creative Commons License